FDA says heartburn drugs can interfere with Plavix

Nov 17, 2009 By MATTHEW PERRONE , AP Business Writer
In this July 28, 2006 file photo, blood thinner medication Plavix is shown in New York. Federal health officials said Tuesday, Nov. 17, 2009, a popular heartburn medication can interfere with the blood thinner Plavix, a drug taken by millions of Americans to reduce risks of heart attack and stroke.(AP Photo/Mark Lennihan, File)

(AP) -- Federal health officials said Tuesday a popular variety of heartburn medications can interfere with the blood thinner Plavix, a drug taken by millions of Americans to reduce risks of heart attack and stroke.

The said the stomach-soothing drugs Prilosec and Nexium cut in half the blood-thinning effect of , known generically as .

Regulators said the key ingredient in the heartburn medications blocks an enzyme the body needs to break down Plavix, muting the drug's full effect. Procter & Gamble's Prilosec is the over-the-counter version of AstraZeneca's Nexium, which was first approved in 2001.

"Patients at risk for heart attacks or strokes who use clopidogrel to prevent blood clots will not get the full effect of this medicine," the agency said in a statement.

Plavix is marketed by Sanofi-Aventis and Bristol-Myers Squibb. With global sales of $8.6 billion last year, it's the world's second-best selling drug behind Pfizer's cholesterol drug Lipitor.

Because Plavix can upset the stomach, it is often prescribed with acid-blocking drugs.

The FDA says patients who need to reduce their acid should take drugs from the H-2 blocker family, which include Johnson & Johnson's Mylanta and Boehringer Ingelheim's Zantac. FDA scientists say there is no evidence those drugs interfere with Plavix's blood clotting.

Nexium and Prilosec are part of a class of drugs known as proton pump inhibitors, but FDA regulators said they don't have enough information to say whether other drugs in that class shouldn't be used with Plavix.

"There's not enough data to tell us how those drugs interact with," the enzyme that activates Plavix, said Mary Ross Southworth, FDA's deputy director for safety of cardiovascular products. "There are ongoing studies looking at those other drugs."

The FDA said the warnings on Plavix have been strengthened based on a 150-patient study submitted by Sanofi over the summer.

Information about the drug interaction between Plavix and certain heartburn medications is not new. Researchers reported last year that taking Plavix with Nexium significantly increased patients' chances of being hospitalized for a , or chest pain.

In January, Sanofi and Bristol-Myers updated Plavix's labeling to advise against using it in combination with certain heartburn drugs.

A Sanofi spokeswoman said Tuesday that the company has bolstered that language labeling.

"We've strengthened the label to say that these drugs should be avoided altogether, not just discouraged," said Noelle Boyd, Sanofi's senior communications director.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: FDA approves new drug for rare genetic disease

add to favorites email to friend print save as pdf

Related Stories

FDA clears Eli Lilly's blood thinner Effient

Jul 10, 2009

(AP) -- The Food and Drug Administration on Friday approved a highly anticipated blood thinner from Eli Lilly, though the drug must carry the agency's sternest warning because of its bleeding risks.

Study: Plavix plus aspirin helps prevent strokes

Mar 31, 2009

(AP) -- Taking the blood thinner Plavix along with aspirin helped prevent strokes and heart attacks in people with a common heartbeat abnormality that puts them at high risk of these problems, doctors reported Tuesday.

FDA toughens warnings on over-the-counter painkillers

Apr 29, 2009

The Food and Drug Administration said Tuesday that it is asking drugmakers to more prominently display safety warnings on the labels of some of the most widely used over-the-counter pain and fever remedies.

Recommended for you

Boxed warnings are common in novel therapeutics

20 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

21 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

22 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0